Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Fibrocell Science (FCSC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,029
  • Shares Outstanding, K 9,758
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,240 K
  • 36-Month Beta 1.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.90
  • Number of Estimates 1
  • High Estimate -0.90
  • Low Estimate -0.90
  • Prior Year -3.25
  • Growth Rate Est. (year over year) +72.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.45 +35.17%
on 12/31/18
2.14 -8.41%
on 01/18/19
+0.46 (+30.67%)
since 12/21/18
3-Month
1.45 +35.17%
on 12/31/18
2.29 -14.41%
on 11/07/18
-0.06 (-2.97%)
since 10/23/18
52-Week
1.45 +35.17%
on 12/31/18
5.17 -62.09%
on 05/25/18
-1.69 (-46.30%)
since 01/23/18

Most Recent Stories

More News
Fibrocell to Present at Phacilitate Leaders World 2019

Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski,...

XON : 7.52 (-6.47%)
FCSC : 1.96 (+0.51%)
Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation

Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that EB Research Partnership,...

XON : 7.52 (-6.47%)
FCSC : 1.96 (+0.51%)
Market Trends Toward New Normal in Fibrocell Science, Sears Hometown and Outlet Stores, Apellis Pharmaceuticals, Sigma Labs, Highpower International, and Nicholas Financial -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Fibrocell Science Inc (NASDAQ:FCSC),...

HPJ : 2.80 (-2.44%)
NICK : 10.80 (+0.19%)
APLS : 12.78 (-4.91%)
SGLB : 2.08 (-0.95%)
FCSC : 1.96 (+0.51%)
SHOS : 2.10 (+2.44%)
Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights

- Company to Host Conference Call and Webcast Today at 8:30 a.m. EST -

XON : 7.52 (-6.47%)
FCSC : 1.96 (+0.51%)
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3

Intrexon (XON) incurs narrower-than-expected loss, while revenues miss estimates in the third quarter of 2018.

OGEN : 0.91 (-1.09%)
XON : 7.52 (-6.47%)
ZIOP : 2.01 (-5.19%)
FCSC : 1.96 (+0.51%)
Intrexon Announces Third Quarter 2018 Financial Results

Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its third quarter financial results...

OGEN : 0.91 (-1.09%)
XON : 7.52 (-6.47%)
ZIOP : 2.01 (-5.19%)
FCSC : 1.96 (+0.51%)
Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights

Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the...

XON : 7.52 (-6.47%)
FCSC : 1.96 (+0.51%)
Fibrocell to Present at Upcoming Industry and Investor Conferences

Fibrocell Science, Inc., (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski,...

XON : 7.52 (-6.47%)
FCSC : 1.96 (+0.51%)
Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and...

XON : 7.52 (-6.47%)
FCSC : 1.96 (+0.51%)
Intrexon Announces First Quarter 2018 Financial Results

Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its first quarter financial results...

AQB : 2.22 (-1.33%)
XON : 7.52 (-6.47%)
FCSC : 1.96 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade FCSC with:

Business Summary

Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous...

See More

Key Turning Points

2nd Resistance Point 2.06
1st Resistance Point 2.00
Last Price 1.96
1st Support Level 1.91
2nd Support Level 1.88

See More

52-Week High 5.17
Fibonacci 61.8% 3.75
Fibonacci 50% 3.31
Fibonacci 38.2% 2.87
Last Price 1.96
52-Week Low 1.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar